Table 1.
Pretreatment characteristics of all eligible patients (n=125)
| Age (years) | |
| Median | 68 |
| Range | 49-81 |
| Race | |
| White | 86 |
| African American | 32 |
| Asian | 2 |
| American Indian/Alaska Native | 1 |
| More than one race | 2 |
| Unknown or not reported | 2 |
| Ethnic Category | |
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 99 |
| Unknown or not reported | 23 |
| Zubrod performance status | |
| 0 | 121 (97%) |
| 1 | 4 (3%) |
| Gleason Score | |
| 2-6 | 13 (10%) |
| 7 | 90 (72%) |
| 8-10 | 22 (18%) |
| PSA | |
| ≤ 10 | 87 (70%) |
| >10 - ≤ 20 | 38 (30%) |
| Median | 7.54 |
| Range | 0.85-19.30 |
| T-Stage | |
| T1 | 67 (54%) |
| T2 | 47 (38%) |
| T3 | 11 (8%) |
| Hormonal Therapy | |
| No | 75 (60%) |
| Yes | 50 (40%) |